News for Annovis Bio, Inc. (ANVS)

Shares of Medpace Holdings, Inc. MEDP rose sharply in pre-market trading after the company reported strong financial results for the second quarter and raised i...

Annovis Bio (ANVS) gains NYSE approval to meet market cap and equity requirements by 2026. Wall Street analysts set an average price target of $18.75, s

NYSE grants Annovis Bio (ANVS) an 18-month period to regain compliance with listing standards. Annovis Bio's stock will continue to trade on the NYSE du

On June 9, 2025, HC Wainwright & Co., a well-regarded financial services firm, revised its price target for Annovis Bio (ANVS). In a recent update, analyst Ragh

H.C. Wainwright has adjusted its price target for Annovis Bio (ANVS), reducing it from $30 to $12 while maintaining a Buy rating for the stock. This revision is

Annovis Bio (ANVS) experienced a remarkable increase in its stock price, climbing 28.3% to reach $3.35. This significant boost in value represents a gain of $0.

On May 15, 2025, Canaccord Genuity, led by analyst Sumant Kulkarni, updated its position on Annovis Bio (ANVS). The firm's analyst maintained a 'Buy' rating for

Cash Position: Cash and cash equivalents increased to $22.2 million as of March 31, 2025, from $10.6 million a year earlier, reflecting a strong liquidity posi

Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis" or the ”œCompany”), a late-stage clinical drug platform company pioneer

Annovis Bio (ANVS) has successfully initiated its pivotal Phase 3 trial for early Alzheimer's disease. The company reported a strong cas

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developin

Several biotech firms are witnessing a remarkable surge in interest, driven by increased search activity, according to InvestingChannel data. Annovis Bio (ANVS)

**media[578946]**

MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative

MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the ”œCompany”), a late-stage clinical drug platform company p

**media[573340]**

MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative

MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS)  (“Annovis” or the “Company”), a clinical-stage drug platform company deve…

**media[534970]**